Johnson & Johnson MedTech today announced new data confirming the benefits of its Abiomed business’ Impella CP system.
The company plans to unveil the newest Impella innovations and feature the new findings during the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco Oct. 25-28.
Additionally, J&J MedTech shared that its evidence led to upgraded recommendations for Impella in recent multi-society guidelines. The guideline updates, which include ACC/AHA, cover the treatment of cardiogenic shock patients. They come on the back of evidence from the DanGer Shock trial published in The New England Journal of Medicine in August.
Findings from DanGer Shock include an absolute mortality reduction of 16.3% compared to standard care at 10 years. On average, Impella CP patients gained approximately 600 additional days alive at 10 years.
Impella CP, the world’s smallest heart pump, is inserted into the heart to temporarily take over the heart’s pumping function. It allows the heart to rest and recover while maintaining the flow of oxygenated blood throughout the body. J&J MedTech says its ninth-generation Impella CP also has new design updates to optimize functionality and enhance ease of use.
New ACC/AHA guidelines now upgrade the Impella CP microaxial intravascular flow pump to a class 2a offering. This follows data demonstrating increased survival in patients with ST-segment elevation myocardial infarction (NSTEMI) and cardiogenic shock.
The American Academy of Thoracic Surgery (AATS) also elevated Impella recommendations in patients with acute myocardial infarction cardiogenic shock (AMICS) to Class I. The European Association for Cardio-Thoracic Surgeons, the American Association for Thoracic Surgery and the Society for Thoracic Surgery also released the first joint guidelines on temporary mechanical circulatory support, inclusive of Impella, in cardiac surgery. They recommend it as a Class I intervention for adults with cardiogenic shock.
“Over the last two decades, we have defined and advanced the science of unloading,” said Navin Kapur, MD, chief medical and scientific officer for heart recovery, Johnson & Johnson MedTech. “We are committed to leading in innovation – as demonstrated through nine generations of Impella CP – and tackling some of the greatest challenges in the cardiovascular space because we want to help as many patients as possible have an opportunity for heart recovery.”
